Actinic keratoses (AKs) are limited areas of irregular epidermal growth on a background of excessive solar exposure. The entire sun-damaged skin is considered a field of cancerization with multiple visible and subclinical lesions. AK management requires field-directed therapies to block lesion relapse and prevent squamous cell carcinoma (SCC).
Lozzi, F., Lanna, C., Mazzeo, M., Garofalo, V., Palumbo, V., Mazzilli, S., et al. (2019). Investigational drugs currently in phase II clinical trials for actinic keratosis. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 28(7), 629-642 [10.1080/13543784.2019.1636030].
Investigational drugs currently in phase II clinical trials for actinic keratosis
Terrinoni A.;Bianchi L.;Campione E.
2019-01-01
Abstract
Actinic keratoses (AKs) are limited areas of irregular epidermal growth on a background of excessive solar exposure. The entire sun-damaged skin is considered a field of cancerization with multiple visible and subclinical lesions. AK management requires field-directed therapies to block lesion relapse and prevent squamous cell carcinoma (SCC).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Investigational drugs currently in phase II clinical trials for actinic keratosis.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
1.55 MB
Formato
Adobe PDF
|
1.55 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
